Biochemical response to ursodeoxycholic acid predicts long‐term outcome in Japanese patients with primary biliary cirrhosis
- 22 March 2011
- journal article
- Published by Wiley in Hepatology Research
- Vol. 41 (4), 310-317
- https://doi.org/10.1111/j.1872-034x.2011.00782.x
Abstract
Aim: There is an ongoing need for predictors of long‐term outcomes for patients with primary biliary cirrhosis (PBC). Biochemical response to ursodeoxycholic acid (UDCA) has been introduced to predict development of symptoms by our group (Ehime criteria) and to predict long‐term outcomes in Western countries (Paris, Barcelona and Rotterdam criteria). The aim of this study was to evaluate whether these criteria are also useful to predict long‐term outcomes in Japanese patients with PBC. Methods: A retrospective chart review was conducted for 227 Japanese patients with PBC. Patients taking UDCA with an observation period of more than 6 months were included in the study. Data collection included demographics, biochemical and serological markers, and histological stage. Four different criteria regarding biochemical response to UDCA were compared and evaluated. Results: In total, 138 patients met the inclusion criteria and underwent analysis. Using the Ehime criteria, the transplant‐free survival rate was significantly higher in responders than in non‐responders (P = 0.010). The Paris criteria also predicted long‐term outcomes in our population (P = 0.003), whereas the Barcelona and Rotterdam criteria showed no such association (P = 0.282 and P = 0.553, respectively). Conclusion: Good biochemical response to UDCA according to the Ehime and Paris criteria is associated with long‐term outcome in Japanese patients with PBC and allows identification of non‐responders who may benefit from further trials. Finally, Ehime criteria should be validated in a different patient cohort.Keywords
This publication has 22 references indexed in Scilit:
- Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosisThe Esophagus, 2009
- Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosisJournal of Hepatology, 2008
- Primary biliary cirrhosisOrphanet Journal of Rare Diseases, 2008
- Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosisJournal of Hepatology, 2006
- The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosisJournal of Hepatology, 2000
- Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosisJournal of Hepatology, 1999
- Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosisJournal of Hepatology, 1999
- A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosisJournal of Hepatology, 1995
- Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 yearsJournal of Hepatology, 1994
- The canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosisJournal of Hepatology, 1994